Beta interferons in clinically isolated syndromes: A meta-analysis

Arquivos de Neuro-Psiquiatria

Volumn 66, Issue 1, 2008, Pages 8-10

  Melo, Ailton ^a,c   Rodrigues, Bernardo ^a   Bar Or, Amit ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b MCGILL UNIVERSITY   (Canada)

^c NONE   (Brazil)

Author keywords

Clinically isolated syndromes; Immunomodulating therapy; Interferon; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; META ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK ASSESSMENT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 42049089539     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2008000100003     Document Type: Article

References (20)

1. Confraveux C, Aimard G, Devic M, et al. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300.
2. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:1227-1231.
3. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
4. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol 2005;58:840-846.
5. PRISMS study group. Randomises double-blind placebo-controlled study of interferon b-1a in relapsing/remitting MS. Lancet 1998;352:1498-1504.
6. Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon b-1a dose response in relapsing-remitting MS. Neurology 1999;53:679-686.
7. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
8. Barkhof F, Filippi M, Miller D, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2050-2069.
9. Tintoré M, Rovira A, Martinez M, et al. Isolated demyelinating syndromes: comparison of different MRI criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 2000;21:702-706.
10. Jadad AR, Moore A, Carrol D. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
11. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582.
12. Jacobs LD, Beck RW, Simon J, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
13. Barkhof F, Polman C, Radue E, et al. Betaferon in newly emerging multiple sclerosis for initial treatment (BENEFIT): magnetic resonance imaging outcomes. ECTRIMS 2005;2:583.
14. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
15. Secondary progressive efficacy clinical trial of recombinant interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-1504.
16. Zanon RG, Oliveira ARL. MHC I upregulation influences astroglial reaction and synaptic plasticity in the spinal cord after sciatic nerve transection. Exp Neurol 2006;200:521-531.
17. Richert ND, Howard T, Frank J, et al. Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis. Neurology 2006;66:551-556.
18. The Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis:experience of the optic neuritis treatment trial. Neurology 1997;49:1404-1413.
19. Sandberg-Wollheim M, Bynke H, Cronqvist S, et al. A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 1990;27:386-393.
20. Masjuan J, Alvarez-Cermen JC, Garcia-Barragan N, et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology 2006;66:576-578.